MDM4 binds ligands via a mechanism in which disordered regions become structured

FEBS Letters

Volumn 584, Issue 14, 2010, Pages 3035-3041

  Sanchez, Maria C ^a   Renshaw, Jonathan G ^b   Davies, Gareth ^b   Barlow, Paul N ^a   Vogtherr, Martin ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

MDM2; MDM4; MDMX; Nuclear magnetic resonance; P53

Indexed keywords

PROTEIN MDM2; PROTEIN MDMX; LIGAND; MDM2 PROTEIN, HUMAN; PROTEIN P53;

ARTICLE; BINDING KINETICS; CONTROLLED STUDY; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; CHEMISTRY; GENETICS; HUMAN; METABOLISM;

HUMANS; LIGANDS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77954177832     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2010.05.058     Document Type: Article

References (23)

1. Brown C.J., Lain S., Verma C.S., Fersht A.R., Lane D.P. Awakening guardian angels: drugging the p53 pathway. Nat. Rev. Cancer 2009, 9:862-873.
2. Harris S.L., Levine A.J. The p53 pathway: positive and negative feedback loops. Oncogene 2005, 24:2899-2908.
3. Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J., Levine A.J. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996, 274:948-953.
4. Vassilev L.T. MDM2 inhibitors for cancer therapy. Trends Mol. Med. 2005, 13:23-31.
5. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., Fotouhi N., nad Liu E.A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848.
6. Showalter S.A., Bruschweiler-Li L., Johnson E., Zhang F., Brüschweiler R. Quantitative lid dynamics of MDM2 reveals differential ligand binding modes of the p53-binding cleft. J. Am. Chem. Soc. 2008, 130:6472-6478.
7. McCoy M.A., Gesell J.J., Senior M.M., Wyss D.F. Flexible lid to the p53-binding domain of human MDM2: implications for p53 regulation. PNAS 2003, 100:1645-1648.
8. Uhrinova S., Uhrin D., Powers H., Watt K., Zhelava D., Fischer P., McInnes C., Barlow P.N. Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. J. Mol. Biol. 2005, 350:587-598.
9. Shvarts A., Steegenga W.T., Riteco N., van Laar T., Dekker P., Bazuine M., van Ham R.C., van Oordt W., Hateboer G., van der Eb A.J., Jochemsen A.G. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J. 1996, 15:5349-5357.
10. Wade M., Wahl G.M. Targeting MDM2 and MDMX in cancer therapy: Better living through medicinal chemistry?. Mol. Cancer Res. 2009, 7:1-11.
11. Marine J.-C.W., Dyer M.A., Jochemsen A.G. MDMX: from bench to bedside. J. Cell Sci. 2007, 120:371-378.
12. Popowicz G.M., Czarna A., Rothweiler U., Szwagierczak A., Krajewski M., Weber L., Holak T.A. Molecular basis for the inhibition of p53 by MDMx. Cell Cycle 2007, 6:2386-2392.
13. Kallen J., Goepfert A., Blechschmidt A., Izaac A., Geiser M., Tavares G., Ramage P., Furet P., Masya K., Lisztwan J. Crystal structure of human MDMX (HdmX) in complex with p53 peptide-analogues reveal surprising conformational changes. J. Biol. Chem. 2009, 284:8812-8821.
14. Pazgier M., Liu M., Zou G., Li C., Li C., Li J., Monbo J., Zella D., Tarasov S.G., Lu W. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. PNAS 2009, 106:4665-4670.
15. Phan J., Li Z., Kasprzak A., Li B., Sebti S., Guida W., Schönbrunn E., Chen J. Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX. J. Biol. Chem. 2010, 285:2174-2183.
16. Keller R. (2004) Optimizing the process of nuclear magnetic resonance spectrum analysis aided resonance assignment. Diss ETH No 15947.
17. Rallapalli R., Strachan G., Cho B., Mercer W.E., Hall D.J. A novel MDMX transcript expressed in a variety of transformed cell lines encodes a truncated protein with potent p53 repressive activity. J. Biol. Chem. 1999, 274:8299-8308.
18. Ericsson U.B., Hallberg B.M., DeTitta G.T., Dekker N., Nordlund P. Thermofluor-based high-throughput stability optimization of proteins for structural studies. Anal. Biochem. 2006, 357:289-298.
19. Segelke B.W. Efficiency analysis of sampling protocols used in protein crystallization screening. J. Cryst. Growth 2001, 232:553-562.
20. McCoy M.A., Gesell J.J., Senior M.M., Wyss D.F. Flexible lid to the p53-binding domain of human Mdm2: implications for p53 regulation. PNAS 2003, 100:1645-1648.
21. Medek A., Hajduk P.J., Mack J., Fesik S.W. The use of differential chemical shifts for determining the binding site location and orientation of protein-bound ligands. J. Am. Chem. Soc. 2000, 122:1241-1242.
22. Berjanskii M.V., Wishart D.S. A simple method to predict protein flexibility using secondary chemical shifts. J. Am. Chem. Soc. 2005, 127:14970-14971.
23. Popowicz G., Czarna A., Wolf S., Wang K., Wang W., Dömling A., Holak T.A. Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery. Cell Cycle 2010, 9:1104-1111.